Rowland & CO Investment Counsel Eli Lilly & CO Transaction History

Rowland & CO Investment Counsel

$486 Million
Q3 2024

A detailed history of Rowland & CO Investment Counsel transactions in Eli Lilly & CO stock. As of the latest transaction made, Rowland & CO Investment Counsel holds 20,619 shares of LLY stock, worth $16.4 Million. This represents 3.76% of its overall portfolio holdings.

Number of Shares

20,619

Previous 20,689 0.34%

Holding current value

$16.4 Million

Previous $18.7 Million 2.48%

% of portfolio

3.76%

Previous 4.12%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 23, 2024	SELL	$772.14 - $960.02 $54,049 - $67,201	-70 Reduced 0.34%	20,619 $18.3 Million
Q2 2024 Jul 29, 2024	SELL	$724.87 - $909.04 $1.25 Million - $1.56 Million	-1,719 Reduced 7.67%	20,689 $18.7 Million
Q1 2024 Apr 08, 2024	SELL	$592.2 - $792.28 $542,455 - $725,728	-916 Reduced 3.93%	22,408 $17.4 Million
Q4 2023 Jan 03, 2024	SELL	$525.19 - $619.13 $387,065 - $456,298	-737 Reduced 3.06%	23,324 $13.6 Million
Q3 2023 Oct 26, 2023	SELL	$434.7 - $599.3 $214,307 - $295,454	-493 Reduced 2.01%	24,061 $12.9 Million
Q2 2023 Aug 04, 2023	SELL	$350.74 - $468.98 $185,190 - $247,621	-528 Reduced 2.11%	24,554 $11.5 Million
Q1 2023 Apr 25, 2023	SELL	$310.63 - $364.82 $468,430 - $550,148	-1,508 Reduced 5.67%	25,082 $8.61 Million
Q4 2022 Jan 04, 2023	SELL	$321.55 - $374.67 $641,813 - $747,841	-1,996 Reduced 6.98%	26,590 $0
Q3 2022 Oct 06, 2022	SELL	$296.48 - $337.87 $168,400 - $191,910	-568 Reduced 1.95%	28,586 $9.24 Million
Q2 2022 Aug 15, 2022	SELL	$278.73 - $327.27 $364,300 - $427,741	-1,307 Reduced 4.29%	29,154 $9.45 Million
Q1 2022 Apr 26, 2022	SELL	$234.69 - $291.66 $600,806 - $746,649	-2,560 Reduced 7.75%	30,461 $8.72 Million
Q4 2021 Feb 14, 2022	SELL	$224.85 - $279.04 $1.18 Million - $1.46 Million	-5,243 Reduced 13.7%	33,021 $9.12 Million
Q3 2021 Nov 08, 2021	BUY	$221.6 - $272.71 $478,212 - $588,508	2,158 Added 5.98%	38,264 $8.84 Million
Q2 2021 Aug 09, 2021	BUY	$180.55 - $233.54 $3,249 - $4,203	18 Added 0.05%	36,106 $8.29 Million
Q1 2021 May 11, 2021	SELL	$164.32 - $212.72 $139,672 - $180,812	-850 Reduced 2.3%	36,088 $6.74 Million
Q4 2020 Feb 11, 2021	SELL	$130.46 - $172.63 $319,887 - $423,288	-2,452 Reduced 6.22%	36,938 $6.24 Million
Q3 2020 Nov 12, 2020	BUY	$146.22 - $169.13 $164,643 - $190,440	1,126 Added 2.94%	39,390 $5.83 Million
Q2 2020 Aug 10, 2020	SELL	$136.42 - $164.18 $153,608 - $184,866	-1,126 Reduced 2.86%	38,264 $6.28 Million
Q1 2020 May 11, 2020	BUY	$119.05 - $147.35 $5,595 - $6,925	47 Added 0.12%	39,390 $5.46 Million
Q4 2019 Jan 28, 2020	SELL	$106.92 - $132.43 $10,692 - $13,243	-100 Reduced 0.25%	39,343 $5.17 Million
Q3 2019 Oct 02, 2019	BUY	$106.79 - $116.16 $152,068 - $165,411	1,424 Added 3.75%	39,443 $4.41 Million
Q2 2019 Jul 09, 2019	SELL	$110.79 - $129.32 $11,189 - $13,061	-101 Reduced 0.26%	38,019 $0
Q1 2019 Apr 10, 2019	SELL	$111.31 - $131.02 $101,626 - $119,621	-913 Reduced 2.34%	38,120 $0
Q4 2018 Feb 12, 2019	BUY	$105.9 - $118.64 $53,373 - $59,794	504 Added 1.31%	39,033 $4.52 Million
Q3 2018 Oct 22, 2018	SELL	$85.86 - $107.31 $61,733 - $77,155	-719 Reduced 1.83%	38,529 $0
Q2 2018 Jul 11, 2018	SELL	$75.7 - $86.88 $380,241 - $436,398	-5,023 Reduced 11.35%	39,248 $0
Q1 2018 Apr 17, 2018	BUY	$74.21 - $87.6 $64,117 - $75,686	864 Added 1.99%	44,271 $0
Q4 2017 Jan 11, 2018	SELL	$81.94 - $87.89 $34,168 - $36,650	-417 Reduced 0.95%	43,407 $0
Q3 2017 Oct 11, 2017	SELL	$77.07 - $85.54 $96,106 - $106,668	-1,247 Reduced 2.77%	43,824 $0
Q3 2017 Oct 11, 2017	BUY	$77.07 - $85.54 $3.47 Million - $3.86 Million	45,071	45,071 $0

Others Institutions Holding LLY

# of Institutions

3,916

Shares Held

765M

Call Options Held

6.34M

Put Options Held

7.96M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $758B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rowland & CO Investment Counsel, based on Form 13F filings with the SEC.

News

Stay updated on Rowland & CO Investment Counsel with notifications on news.

Account

Rowland & CO Investment Counsel Eli Lilly & CO Transaction History